

NARCAN[®] (naloxone HCl) **NASAL SPRAY 4mg**

Please join us for a brief and informative update:

NEW WEBINAR

Naloxone in the Pharmacy: Engaging At-Risk Patients in Conversation



Presented By:

Tiffany Chan, PharmD, BCPS

Zachariah Hicks, PharmD, MBA

To register for this webinar and select the date/time you would like to attend, RSVP below:

RSVP NOW

**For your convenience, multiple
(30-minute) sessions are available.**

**June 8th, 2021 and June 9th, 2021
8:30 AM (EDT); 12:30 PM (EDT); 5:30 PM (EDT)**

Dial-in webinar instructions will be provided via email at time of RSVP.

We hope this session will be of value to your organization's pharmacist.

INDICATION AND USAGE

NARCAN[®] (naloxone HCl) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN[®] Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN[®] Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN[®] Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. Monitor for the development of opioid withdrawal.

In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes.

Abrupt Postoperative Reversal of Opioid Depression: Abrupt postoperative reversal of opioid depression may result in nausea, vomiting, sweating, tremulousness, tachycardia, hypotension, hypertension, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest. Serious sequelae of these events, including coma and death, have been reported. These events have primarily occurred in patients who had pre-existing cardiovascular (CV) disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone HCl.

Adverse Reactions: The following adverse reactions were observed in a NARCAN[®] Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.

NNS HCP ISI 08/2020

Please see [full Prescribing Information](#).

For more information on Emergent BioSolutions' Privacy Policy, please [click here](#).

This email is intended for US healthcare professionals only.

To be removed from this list, please [click here](#).

Emergent Devices Inc.
401 Plymouth Road
Suite 400
Plymouth Meeting, PA 19462



©2021 Emergent Devices Inc. Plymouth Meeting, PA. All rights reserved.
NARCAN[®] is a registered trademark of Emergent Operations Ireland Limited.
Emergent Devices Inc. and Emergent Operations Ireland Limited are
wholly-owned subsidiaries of Emergent BioSolutions Inc.
PP-NAR4-US-00480. 05/2021.